🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Neuronetics, Inc. (STIM)
NASDAQ: STIM · Real-Time Price · USD
1.250
+0.010 (0.81%)
Nov 20, 2026, 4:00 PM EST - Market closed

Company Description

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.

The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.

The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. has a strategic collaboration with ANT Neuro to expand the capabilities of the NeuroStar advanced therapy system with advanced image-guided navigation technology.

The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics, Inc.
Neuronetics logo
CountryUnited States
Founded2003
IPO DateJun 28, 2018
IndustryMedical Devices
SectorHealthcare
Employees658
CEODaniel Reuvers

Contact Details

Address:
3222 Phoenixville Pike
Malvern, Pennsylvania 19355
United States
Phone877 600 7555
Websiteneurostar.com

Stock Details

Ticker SymbolSTIM
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001227636
CUSIP Number64131A105
ISIN NumberUS64131A1051
SIC Code3841

Key Executives

NamePosition
Daniel L. ReuversChief Executive Officer, President and Director
Nir Naor C.F.A., CPA, L.L.M., M.B.A.Executive Vice President, Chief Financial Officer, Corporate Secretary, Principal Financial and Accounting Officer and Treasurer
Robert GreeneSenior Vice President of Sales
Cory S. AndersonExecutive Vice President and General Manager of Greenbrook

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13D/AFiling
Nov 16, 2026SCHEDULE 13D/AFiling
Nov 12, 20268-K/A[Amend] Current report
Nov 12, 20268-KCurrent Report
Nov 12, 2026424B5Filing
Nov 10, 2026424B5Filing
Nov 10, 20268-KCurrent Report
Nov 10, 2026144Filing
Nov 4, 202610-QQuarterly Report
Nov 4, 20268-KCurrent Report
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides